<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Eur J Hum Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur. J. Hum. Genet</journal-id>
<journal-title-group>
<journal-title>European Journal of Human Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1018-4813</issn>
<issn pub-type="epub">1476-5438</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27759030</article-id>
<article-id pub-id-type="pmc">5159772</article-id>
<article-id pub-id-type="pii">ejhg2016139</article-id>
<article-id pub-id-type="doi">10.1038/ejhg.2016.139</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Complete loss of function of the ubiquitin ligase HERC2 causes a severe neurodevelopmental phenotype</article-title>
<alt-title alt-title-type="running">Expansion of HERC2-related disease</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Morice-Picard</surname>
<given-names>Fanny</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Benard</surname>
<given-names>Giovanni</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rezvani</surname>
<given-names>Hamid R</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lasseaux</surname>
<given-names>Eulalie</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Simon</surname>
<given-names>Delphine</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moutton</surname>
<given-names>Sébastien</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rooryck</surname>
<given-names>Caroline</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lacombe</surname>
<given-names>Didier</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baumann</surname>
<given-names>Clarisse</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arveiler</surname>
<given-names>Benoit</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2987-2932</contrib-id>
</contrib>
<aff id="aff1"><label>1</label><institution>Univ. Bordeaux, Maladies Rares: Génétique et Métabolisme (MRGM) EA4576</institution>, Bordeaux, <country>France</country></aff>
<aff id="aff2"><label>2</label><institution>CHU de Bordeaux, Service de Génétique Médicale</institution>, Bordeaux, <country>France</country></aff>
<aff id="aff3"><label>3</label><institution>INSERM, Biothérapies des Maladies Génétiques et Cancers</institution>, Bordeaux, <country>France</country></aff>
<aff id="aff4"><label>4</label><institution>Hôpital Robert Debré, Service de Génétique Médicale</institution>, Paris, <country>France</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Laboratoire Maladies Rares - Génétique et Métabolisme (EA 4576) Ecole de Sages-Femmes Hôpital Pellegrin</institution>, 1 Place Amélie Raba-Léon, Bordeaux Cedex 33076, <country>France</country>. Tel: +33 5 57 82 03 55; Fax: +33 5 56 79 56 48; E-mail: <email>fanny.morice-picard@chu-bordeaux.fr</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>10</month>
<year>2016</year>
</pub-date>
<volume>25</volume>
<issue>1</issue>
<fpage>52</fpage>
<lpage>58</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>03</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>08</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>09</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Macmillan Publishers Limited, part of Springer Nature.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Macmillan Publishers Limited, part of Springer Nature.</copyright-holder>
</permissions>
<abstract>
<p>The ubiquitin-proteasome pathway is involved in the pathogenesis of several neurogenetic diseases. We describe a Mauritanian patient harboring a homozygous deletion restricted to two contiguous genes <italic>HERC2</italic> and <italic>OCA2</italic> and presenting with severe developmental abnormalities. The deletion causes the complete loss of HERC2 protein function, an E3-ubiquitin ligase. HERC2 is known to target XPA and BRCA1 for degradation and a mechanism whereby it is involved in DNA repair and cell cycle regulation. We showed that loss of HERC2 function leads to the accumulation of XPA and BRCA1 in the patient's fibroblasts and generates decreased sensitivity to apoptosis and increased level of DNA repair. Our data describe for the first time the phenotypic consequences, both at the clinical and cellular levels, of a complete loss of HERC2 function in a patient. They strongly suggest that profound ubiquitin ligase – associated dysfunction is responsible for the severe phenotype in this patient, and that dysfunction of this pathway may be involved in other patients with similar neurodevelopmental diseases.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>